December 16, 2015 / 1:41 PM / in 2 years

BRIEF-Valeant CEO says double digit organic growth will continue

Dec 16 (Reuters) - Valeant Pharmaceuticals International Inc

* Valeant CEO says will not budget research and development as a certain percentage of sales, but will review it regularly

* Valeant CEO says Addyi sales expected at $100 million to $150 million in 2016

* Valeant says anticipates $250 million loss in revenue in q4 due to Philidor situation

* Valeant says prescriptions dropped 20 percent in the fourth quarter as it lost all Philidor covered scripts

* Valeant CEO says double digit organic growth will continue in the years after 2016

* Valeant CEO says employee retention plan has worked and has only lost two sales representatives in the dermatology business

* Valeant says canceled all price increases during the fourth quarter

* Valeant says employee retention bonuses targeted at $75 million in 2016 (Reporting By Caroline Humer)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below